Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBITDA Margin (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed EBITDA Margin for 9 consecutive years, with 21.25% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin rose 2780.0% to 21.25% in Q4 2025 year-over-year; TTM through Dec 2025 was 2.26%, a 4107.0% increase, with the full-year FY2025 number at 2.26%, up 4107.0% from a year prior.
  • EBITDA Margin was 21.25% for Q4 2025 at Akebia Therapeutics, down from 0.92% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 20.09% in Q2 2022 to a low of 156.94% in Q2 2021.
  • A 5-year average of 54.19% and a median of 39.55% in 2023 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 27750bps in 2021; the steepest drop was -6438bps in 2021.
  • Akebia Therapeutics' EBITDA Margin stood at 121.13% in 2021, then skyrocketed by 95bps to 5.56% in 2022, then surged by 157bps to 3.15% in 2023, then crashed by -1659bps to 49.04% in 2024, then surged by 57bps to 21.25% in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EBITDA Margin are 21.25% (Q4 2025), 0.92% (Q3 2025), and 0.4% (Q2 2025).